Universitéde Montreal

Rtp Pharma, Inc.

Cyclosporine Therapeutics Limited

Iskandar Moussa

Louis Cartilier

Indu Parikh

Stephane Buczkowski

Chafic Chebli

Nuala M Clarke

Zeibunnissa Ramtoola

Aerosol formulations containing stabilized particles of drug microparticles with a mean size range of 0.1 to 10 microns coated with a membrane-forming, amphiphatic lipid and dispersed in 1,1,1,2-tetaafluoroetiane (HFA 134a) of 1,1,1,2,3,3,3-heptafluoropropane (HFA 227) propellant.

Dry aerosol suspension of phospholipid-stabilized drug microparticles in

A pharmaceutical sustained release tablet for oral administration is made of a compressed blend of at least two dry powders including a powder of a pharmaceutical drug and a powder of a sustained release matrix for the drug. The sustained release matrix is made of substituted amylose prepared by reacting, in a basic medium, amylose with an organic substituent having a reactive function that reacts with the hydroxy groups of the amylose molecule. This substituent is preferably an epoxy or halogen alkane or alcohol with such a matrix controlled and sustained release of a drug are achieved with a remarkable close-to-linear profile and a release time of from 9 to 20 hours.

Substituted amylose as a matrix for sustained drug release

Growing community of inventors

Montreal, Canada

Iskandar Moussa